Raia Drogasil S.A. (RADLY) Stock Analysis

Raia Drogasil S.A. (RADLY) Healthcare & Pipeline Overview

Raia Drogasil S.A. is a prominent player in Brazil's pharmaceutical retail sector, with a robust network of over 2,500 stores and a diverse product offering that includes medicines, cosmetics, and personal care items, catering to a wide range of consumer needs.

What Is the Investment Thesis for RADLY?

With a market capitalization of $6.66B and a P/E ratio of 21.30, the company demonstrates solid profitability, reflected in its profit margin of 2.9% and gross margin of 27.8%. The ongoing expansion of its drugstore network and the introduction of new product lines are expected to drive revenue growth. Additionally, the company's low beta of 0.11 indicates lower volatility compared to the broader market, appealing to risk-averse investors. The dividend yield of 2.31% further enhances its attractiveness as a stable income-generating asset. However, investors may want to evaluate potential risks, including regulatory changes in the healthcare sector and competition from both local and international players.

Based on FMP financials and quantitative analysis

RADLY Key Highlights

Market Cap of $6.66B indicates a strong presence in the Brazilian pharmaceutical retail market.

• P/E ratio of 21.30 suggests a premium valuation compared to peers, reflecting investor confidence.
• Profit margin of 2.9% and gross margin of 27.8% highlight effective cost management and operational efficiency.
• Beta of 0.11 indicates lower stock volatility, appealing to conservative investors.
• Dividend yield of 2.31% provides a steady income stream for shareholders.

Who Are RADLY's Competitors?

RADLY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are RADLY's Key Strengths?

Strong market presence with over 2,500 stores.

• Diverse product portfolio catering to various consumer needs.
• Established brand with high consumer trust.
• Efficient operational management leading to stable profit margins.

What Are RADLY's Weaknesses?

Dependence on the Brazilian market for revenue.

• Relatively low profit margin compared to industry leaders.
• Limited international presence compared to global competitors.
• Potential vulnerability to regulatory changes in the healthcare sector.

What Could Drive RADLY Stock Higher?

RADLY catalyst: Expansion of store network with plans to open new locations in underserved areas of Brazil.

• Continued growth in e-commerce sales as the company enhances its online platform.
• Diversification of product offerings to include more specialty medicines and health products.
• Strategic partnerships with healthcare providers to create integrated health solutions.
• Focus on improving customer experience through enhanced in-store services and technology.

What Are the Key Risks for RADLY?

Regulatory changes impacting the pharmaceutical retail sector.

• Intense competition from both local and international pharmacy chains.
• Economic fluctuations affecting consumer spending on healthcare products.
• Supply chain disruptions that could impact product availability.
• Currency risk associated with fluctuations in the Brazilian real.

What Are the Growth Opportunities for RADLY?

• Expansion of Store Network: Raia Drogasil plans to increase its footprint by opening new drugstores in underserved regions of Brazil. The Brazilian pharmacy market is projected to grow at a CAGR of 10% over the next five years, providing a significant opportunity for Raia Drogasil to capture additional market share and enhance its revenue streams.
• E-commerce Growth: With the rise of online shopping, Raia Drogasil is investing in its e-commerce platform to reach a broader customer base. The online pharmaceutical market in Brazil is expected to grow by 20% annually, allowing the company to tap into a growing segment of tech-savvy consumers seeking convenient access to health products.
• Diversification of Product Offerings: The company is expanding its range of specialty medicines and health-related products, targeting specific consumer needs. This strategy aligns with the increasing consumer demand for personalized healthcare solutions, expected to drive sales growth in the specialty segment by approximately 15% over the next few years.
• Strategic Partnerships: Raia Drogasil is exploring partnerships with healthcare providers and insurance companies to offer integrated health solutions. This approach is anticipated to enhance customer loyalty and increase foot traffic to its stores, contributing to a projected revenue growth of 8% annually.
• Focus on Customer Experience: By enhancing in-store experiences and leveraging technology for better customer engagement, Raia Drogasil aims to improve customer retention rates. The emphasis on customer service is expected to yield a 5% increase in repeat purchases over the next year.

What Are RADLY's Competitive Advantages?

• Established brand recognition and trust among Brazilian consumers.
• Extensive network of drugstores providing convenient access to products.
• Diverse product offerings catering to a wide range of consumer needs.
• Strong customer service through telesales and call centers.
• Strategic location of stores in high-traffic areas enhancing visibility.

What Does RADLY Do?

Founded in 1905, Raia Drogasil S.A. has evolved into one of Brazil's largest pharmacy chains, with a mission to provide accessible healthcare products to the population. Headquartered in São Paulo, the company operates a vast network of 2,530 drugstores across 26 Brazilian states. Over the years, Raia Drogasil has expanded its offerings beyond traditional pharmaceuticals to include perfumery, personal care, beauty products, cosmetics, dermocosmetics, and specialty medicines. This diversification has enabled the company to cater to a broad customer base, enhancing its market presence. Raia Drogasil also utilizes modern marketing strategies, including telesales and call centers located in São Paulo, Tocantins, and Pernambuco, to reach customers effectively. The company's commitment to quality and customer service has solidified its reputation in the Brazilian healthcare sector, making it a trusted choice for consumers seeking a variety of health and wellness products.

What Products and Services Does RADLY Offer?

• Retail sale of medicines and pharmaceuticals in Brazil.
• Offer a wide range of personal care and beauty products.
• Provide cosmetics and dermocosmetics for skincare.
• Market specialty medicines for chronic and complex conditions.
• Utilize telesales and call centers for customer outreach.
• Operate a network of over 2,500 drugstores across 26 states.

How Does RADLY Make Money?

• Generate revenue through the retail sale of pharmaceuticals and health-related products.
• Leverage a vast network of physical stores to reach consumers directly.
• Utilize e-commerce platforms to expand sales channels and customer reach.
• Implement telesales and call center services to enhance customer service and sales.
• Diversify product offerings to cater to various consumer needs and preferences.

What Industry Does RADLY Operate In?

The pharmaceutical retail industry in Brazil is characterized by a growing demand for healthcare products, driven by an aging population and increasing health awareness among consumers. The market is expected to expand as more individuals seek convenient access to medications and personal care products. Raia Drogasil S.A. is well-positioned within this competitive landscape, facing rivals such as MatsukiyoCocokara & Co. (MSMKF), Getinge AB (publ) (GNGBY), and Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY). The overall pharmaceutical market in Brazil is projected to grow significantly, providing ample opportunities for established players like Raia Drogasil to capture market share and enhance profitability.

Who Are RADLY's Key Customers?

• General public seeking over-the-counter and prescription medications.
• Consumers interested in personal care and beauty products.
• Patients requiring specialty medicines for chronic conditions.
• Health-conscious individuals looking for dermocosmetics and skincare solutions.
• Online shoppers seeking convenience in purchasing health products.

Company Profile

Raia Drogasil S.A. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in São Paulo, BR. The company is led by CEO Renato Raduan. RADLY has traded publicly since 2016.

Return on equity for Raia Drogasil S.A. stands at 18.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.1%, showing how much profit it generates from its asset base. RADLY trades at a trailing price-to-earnings ratio of 21.30, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.7%, the inverse of the P/E and a quick read on earnings relative to price.

RADLY Valuation & Market Position

With a $6.66B market cap, Raia Drogasil S.A. sits in the mid-cap segment of the market.

Quarterly Financial Performance: Raia Drogasil S.A.

Revenue for Raia Drogasil S.A. came in at $2.22B during Q2 FY2026, a 7.0% improvement versus the preceding quarter. The company recorded net income of $85.2M, with diluted EPS of $0.05. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, RADLY averaged $0.04 in diluted EPS.

Raia Drogasil S.A.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.53 places it in the safe zone, indicating low near-term bankruptcy risk.

Raia Drogasil S.A. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 6.8% above estimates on average.

RADLY Financials

RADLY Latest News

RADLY Analyst Consensus

RADLY MoonshotScore

Common Questions About RADLY (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources